Financials Mesa Laboratories, Inc.

Stocks

MLAB

US59064R1095

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 21:15:44 12/06/2026 +03			5-day change	1st Jan Change
106.36 ^USD	-0.93%		+3.28%	+36.69%

06-03	Tranche Update on Mesa Laboratories, Inc.'s Equity Buyback Plan announced on November 10, 2005.	CI
05-27	Mesa Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI

Projected Income Statement: Mesa Laboratories, Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	184.3	219.1	216.2	241	249.1	259.2	272.2
Change	-	18.85%	-1.32%	11.47%	3.38%	4.03%	5.02%
EBITDA ¹	41.16	49.68	50.5	56.74	63.49	63.2	67.1
Change	-	20.7%	1.66%	12.34%	11.9%	-0.45%	6.17%
EBIT ¹	37.9	45.82	50.5	51.36	58.23	65.7	70.4
Change	-	20.9%	10.22%	1.68%	13.39%	12.82%	7.15%
Interest Paid ¹	-3.885	-4.77	-5.697	-11.86	-10.69	-14.3	-13
Earnings before Tax (EBT) ¹	3.574	-0.389	-275.6	5.961	12.01	10.23	16.2
Change	-	-110.88%	-70,760.67%	102.16%	101.54%	-14.82%	58.31%
Net income ¹	1.871	0.93	-254.2	-1.974	6.712	7.567	12.13
Change	-	-50.29%	-27,438.28%	99.22%	440.02%	12.73%	60.35%
Announcement Date	5/31/22 A	5/25/23 A	6/5/24 A	5/28/25 A	5/27/26 A	-	-

¹USD in Million

Estimates

Fiscal Period: March	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4	2028 Q1	2028 Q2	2028 Q3	2028 Q4
Net sales ¹	34.92	35.84	54.7	58.88	50.45	58.75	54.29	55.59	50.64	53.16	53.47	58.9	58.17	57.83	62.84	62.14	59.54	60.74	65.13	63.72	60.87	62.8	67.43	68.03	63.3	67	69.5	70.2
Change	-	2.63%	52.61%	7.65%	-14.31%	16.44%	-7.6%	2.4%	-8.9%	4.98%	0.58%	10.16%	-1.25%	-0.58%	8.66%	-1.12%	-4.17%	2.01%	7.23%	-2.15%	-4.48%	3.18%	7.38%	0.89%	-6.96%	5.85%	3.73%	1.01%
EBITDA ¹	9.892	10.52	8.028	12.72	6.972	16.42	14.04	12.25	10.44	11.22	11.98	14.94	16.74	14.35	14.79	12.26	12.9	15.23	17.07	18.28	13.1	13.2	18.1	18.8	16.3	16.4	17.1	17.3
Change	-	6.32%	-23.67%	58.5%	-45.21%	135.53%	-14.51%	-12.73%	-14.8%	7.48%	6.74%	24.74%	12.1%	-14.29%	3.04%	-17.12%	5.27%	18.07%	12.07%	7.08%	-28.34%	0.76%	37.12%	3.87%	-13.3%	0.61%	4.27%	1.17%
EBIT ¹	9.136	10.12	13.78	11.65	6.158	15.47	12.86	10.71	9.524	10.31	10.9	14.94	15.34	12.83	13.68	10.9	11.5	13.92	15.8	17.02	14.5	15.25	18.45	17.5	17	17.2	17.3	17.2
Change	-	10.72%	36.23%	-15.44%	-47.16%	151.25%	-16.91%	-16.68%	-11.09%	8.23%	5.75%	37.03%	2.7%	-16.34%	6.61%	-20.32%	5.47%	21.05%	13.54%	7.68%	-14.78%	5.17%	20.98%	-5.15%	-2.86%	1.18%	0.58%	-0.58%
Charge d'intérêts ¹	-0.874	-0.815	-1.018	-1.238	-1.014	-1.214	-1.162	-1.38	-1.048	-0.905	-1.856	-1.888	-2.842	-3.018	-2.842	-2.519	-2.198	-2.862	-3.036	-2.596	-3.667	-3.633	-3.567	-3.433	-4.7	-4.7	-4.9	-4.6
Earnings before Tax (EBT) ¹	1.418	4.543	-2.341	-0.046	-5.412	3.384	1.916	-0.277	-0.937	-1.325	1.946	-275.3	3.905	3.812	-2.217	0.461	7.012	1.999	4.596	-1.593	0.1	0.7667	4.8	4.567	1.7	2.2	2.5	2.6
Change	-	220.38%	-151.53%	98.04%	-11,665.22%	162.53%	-43.38%	-114.46%	-238.27%	-41.41%	246.87%	-14,248.61%	101.42%	-2.38%	-158.16%	120.79%	1,421.04%	-71.49%	129.91%	-134.66%	106.28%	666.67%	526.08%	-4.86%	-62.77%	29.41%	13.64%	4%
Net income ¹	1.995	3.72	-2.06	-1.784	-1.438	1.306	0.451	0.611	-0.549	-1.23	2.116	-254.6	3.388	3.428	-1.676	-7.114	4.742	2.476	3.63	-4.136	-	0.5333	3.567	3.4	1.3	1.7	2.2	2.1
Change	-	86.47%	-155.38%	13.4%	19.39%	190.82%	-65.47%	35.48%	-189.85%	-124.04%	272.03%	-12,131.33%	101.33%	1.18%	-148.89%	-324.46%	166.66%	-47.79%	46.61%	-213.94%	-	-	568.75%	-4.67%	-61.76%	30.77%	29.41%	-4.55%
Announcement Date	8/5/21 A	11/4/21 A	2/3/22 A	5/31/22 A	8/4/22 A	11/3/22 A	2/6/23 A	5/25/23 A	8/3/23 A	11/6/23 A	2/5/24 A	6/5/24 A	8/5/24 A	11/7/24 A	2/4/25 A	5/28/25 A	8/5/25 A	11/6/25 A	2/3/26 A	5/27/26 A	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Mesa Laboratories, Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028
Net Debt	169	150	-	-	-	-	-
Change	-	-11.24%	-	-	-	-	-
Announcement Date	5/31/22 A	5/25/23 A	6/5/24 A	5/28/25 A	5/27/26 A	-	-

Estimates

Cash Flow Forecast: Mesa Laboratories, Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028
CAPEX ¹	4.432	4.544	2.567	4.249	3.25	4.25	4.25
Change	-	2.53%	-43.51%	65.52%	-23.51%	30.77%	0%
Free Cash Flow (FCF) ¹	34.79	23.44	41.57	42.56	39.58	40	44.3
Change	-	-32.63%	77.34%	2.39%	-7%	1.06%	10.75%
Announcement Date	5/31/22 A	5/25/23 A	6/5/24 A	5/28/25 A	5/27/26 A	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Mesa Laboratories, Inc.

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	22.33%	22.68%	23.36%	23.54%	25.48%	24.39%	24.65%
EBIT Margin (%)	20.56%	20.92%	23.36%	21.31%	23.37%	25.35%	25.87%
EBT Margin (%)	1.94%	-0.18%	-127.5%	2.47%	4.82%	3.95%	5.95%
Net margin (%)	1.01%	0.42%	-117.6%	-0.82%	2.69%	2.92%	4.46%
FCF margin (%)	18.87%	10.7%	19.23%	17.66%	15.89%	15.43%	16.28%
FCF / Net Income (%)	1,859.49%	2,520.32%	-16.35%	-2,155.98%	589.71%	528.63%	365.11%
Profitability
ROA	6.69%	6.34%	-	7.51%	10.78%	15.7%	17.5%
ROE	10.94%	11.03%	-	21.65%	26.83%	36.2%	32.5%
Financial Health
Leverage (Debt/EBITDA)	4.11x	3.03x	-	-	-	-	-
Debt / Free cash flow	4.86x	6.42x	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	2.4%	2.07%	1.19%	1.76%	1.3%	1.64%	1.56%
CAPEX / EBITDA (%)	10.77%	9.15%	5.08%	7.49%	5.12%	6.72%	6.33%
CAPEX / FCF (%)	12.74%	19.39%	6.18%	9.98%	8.21%	10.62%	9.59%
Items per share
Cash flow per share ¹	7.345	5.22	8.194	8.635	7.696	5.99	6.34
Change	-	-28.94%	56.98%	5.38%	-10.86%	-22.17%	5.84%
Dividend per Share ¹	0.64	0.64	0.64	0.64	0.64	0.64	0.64
Change	-	0%	0%	0%	0%	0%	0%
Book Value Per Share ¹	74.79	73.28	26.95	29.3	33.71	37.49	40.53
Change	-	-2.01%	-63.22%	8.7%	15.06%	11.21%	8.11%
EPS ¹	0.35	0.17	-47.2	-0.36	1.21	1.36	2.143
Change	-	-51.43%	-27,864.71%	99.24%	436.11%	12.4%	57.6%
Nbr of stocks (in thousands)	5,246	5,346	5,394	5,434	5,525	5,525	5,525
Announcement Date	5/31/22 A	5/25/23 A	6/5/24 A	5/28/25 A	5/27/26 A	-	-